P. Sun

Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas

John E. Murphy, D. Brophy, E. Martin, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

A first‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐06741086, an anti‐tissue factor pathway inhibitor mAb, in healthy volunteers

S. Arkin, D. Pittman, P. Sun, 2018, Journal of thrombosis and haemostasis : JTH.

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Michael Wang, L. Boggio, J. Mahlangu, 2022, British journal of haematology.

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease

R. Gurrell, S. Duvvuri, N. DeMartinis, 2018, Clinical Drug Investigation.